HROW240719C21000
- 1.50
- +0.35+30.43%
Harrow Newsroom
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator
Taaleem Signs Exclusive Operations, Ownership Deal With Harrow International Schools
Taaleem Holdings (DFM:TAALEEM) signed a master agreement with Harrow International Schools, according to a Monday release. The United Arab Emirates-based education company will solely own and manage H
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $30
Craig-Hallum analyst Chase Knickerbocker maintains $Harrow(HROW.US)$ with a buy rating, and sets the target price at $30.According to TipRanks data, the analyst has a success rate of 43.3% and a total
Harrow Is Maintained at Buy by Craig-Hallum
Harrow Is Maintained at Buy by Craig-Hallum
Harrow Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 50% Craig-Hallum $26 → $30 Maintains Buy 06/03/2024 25% Lake Street $20 → $25 Maintains Buy 05/
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $30 From $26
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, be
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday.Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings a
Harrow Rises 15% In Pre-market
Market-Moving News for June 20th
HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also th
Harrow Shares Are Trading Higher After the Company Announced the Manufacture of the First of Three Commercial-scale Process Performance Qualification Batches of TRIESENCE 40 Mg/mL. Also the Company Announced That the Second and Third Required PPQ...
Harrow Shares Are Trading Higher After the Company Announced the Manufacture of the First of Three Commercial-scale Process Performance Qualification Batches of TRIESENCE 40 Mg/mL. Also the Company An
Harrow Hopes To Relaunch Triesence This Year
Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Says Second & Third Required PPQ Batches Are Scheduled
Harrow Announce Manufacture Of First Of Three Commercial-Scale Process Performance Qualification Batches Of Triesence For Visualization During Vitrectomy And Ocular Inflammatory Conditions, Harrow Say
Express News | Harrow: IF Ppq Batches Meet Specifications, New Triesence Production Process to Be Deemed Complete, Allowing Co to Relaunch During 2024
Express News | Harrow Inc: Successful Manufacture of Triesence Ppq Batch
Express News | Harrow Provides Triesence® Relaunch Update
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $29
B.Riley Financial analyst Mayank Mamtani maintains $Harrow(HROW.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 25.4% and a
Express News | Correction: Melt pharmaceutical (not "harrow Inc"): expected to announce earnings prospects in the fourth quarter of 2024.
Express News | Corrected-Melt Pharmaceuticals (Not 'harrow Inc'): Topline Readout Expected in Q4 2024